Clinical significance of BTLA gene expression and rs1982809 polymorphism in pan-cancer.

IF 1.1 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nucleosides, Nucleotides & Nucleic Acids Pub Date : 2024-01-01 Epub Date: 2023-12-20 DOI:10.1080/15257770.2023.2296615

Xueren Gao, Yichang Gao, Shiyu Pan, Lin Yang

{"title":"Clinical significance of BTLA gene expression and rs1982809 polymorphism in pan-cancer.","authors":"Xueren Gao, Yichang Gao, Shiyu Pan, Lin Yang","doi":"10.1080/15257770.2023.2296615","DOIUrl":null,"url":null,"abstract":"The association between the B and T lymphocyte attenuator (BTLA) gene rs1982809 polymorphism and cancer susceptibility has been reported, but these findings are inconsistent. In addition to clarifying the relationship between the rs1982809 polymorphism and cancer susceptibility, the current study also explored the clinical significance of BTLA gene expression. The GSCA tool and Stata software were used to explore the association between BTLA gene expression and tumor stage, immune infiltration, survival prognosis, and drug sensitivity for pan-cancer, and the association of BTLA gene rs1982809 polymorphism with cancer susceptibility, respectively. BTLA gene expression was associated not only with the pathologic stages of thyroid carcinoma, skin cutaneous melanoma, and kidney renal clear cell carcinoma, but also with immune infiltration in 33 types of cancers. In addition, BTLA gene expression was linked to survival prognosis in 8 types of cancers and the sensitivity of 255 drugs such as 5-Fluorouracil, docetaxel, and methotrexate. A meta-analysis of 7 relevant studies with 4002 cancer patients and 5278 healthy controls showed that the BTLA gene rs1982809 polymorphism was unrelated to cancer susceptibility under all genetic models. However, a country-based stratification analysis suggested that the rs1982809 polymorphism could reduce cancer susceptibility in Polish and Tunisian populations. In conclusion, BTLA is expected to serve as a prognostic marker and therapeutic target for certain cancers, and the rs1982809 polymorphism is expected to serve as a cancer susceptibility marker in Polish and Tunisian populations.","PeriodicalId":19343,"journal":{"name":"Nucleosides, Nucleotides & Nucleic Acids","volume":" ","pages":"1065-1076"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nucleosides, Nucleotides & Nucleic Acids","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/15257770.2023.2296615","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The association between the B and T lymphocyte attenuator (BTLA) gene rs1982809 polymorphism and cancer susceptibility has been reported, but these findings are inconsistent. In addition to clarifying the relationship between the rs1982809 polymorphism and cancer susceptibility, the current study also explored the clinical significance of BTLA gene expression. The GSCA tool and Stata software were used to explore the association between BTLA gene expression and tumor stage, immune infiltration, survival prognosis, and drug sensitivity for pan-cancer, and the association of BTLA gene rs1982809 polymorphism with cancer susceptibility, respectively. BTLA gene expression was associated not only with the pathologic stages of thyroid carcinoma, skin cutaneous melanoma, and kidney renal clear cell carcinoma, but also with immune infiltration in 33 types of cancers. In addition, BTLA gene expression was linked to survival prognosis in 8 types of cancers and the sensitivity of 255 drugs such as 5-Fluorouracil, docetaxel, and methotrexate. A meta-analysis of 7 relevant studies with 4002 cancer patients and 5278 healthy controls showed that the BTLA gene rs1982809 polymorphism was unrelated to cancer susceptibility under all genetic models. However, a country-based stratification analysis suggested that the rs1982809 polymorphism could reduce cancer susceptibility in Polish and Tunisian populations. In conclusion, BTLA is expected to serve as a prognostic marker and therapeutic target for certain cancers, and the rs1982809 polymorphism is expected to serve as a cancer susceptibility marker in Polish and Tunisian populations.

查看原文本刊更多论文

泛癌中 BTLA 基因表达和 rs1982809 多态性的临床意义。

B 和 T 淋巴细胞减弱因子（BTLA）基因 rs1982809 多态性与癌症易感性之间的关系已有报道，但这些研究结果并不一致。本研究除了阐明 rs1982809 多态性与癌症易感性之间的关系外，还探讨了 BTLA 基因表达的临床意义。本研究利用GSCA工具和Stata软件分别探讨了BTLA基因表达与肿瘤分期、免疫浸润、生存预后、泛癌药物敏感性的关系，以及BTLA基因rs1982809多态性与癌症易感性的关系。BTLA基因的表达不仅与甲状腺癌、皮肤黑色素瘤和肾透明细胞癌的病理分期有关，还与33种癌症的免疫浸润有关。此外，BTLA 基因表达还与 8 种癌症的生存预后以及 255 种药物（如 5-氟尿嘧啶、多西他赛和甲氨蝶呤）的敏感性有关。一项对 7 项相关研究（包括 4002 名癌症患者和 5278 名健康对照者）进行的荟萃分析表明，在所有遗传模型中，BTLA 基因 rs1982809 多态性与癌症易感性无关。然而，基于国家的分层分析表明，rs1982809 多态性可降低波兰和突尼斯人群的癌症易感性。总之，BTLA有望成为某些癌症的预后标记和治疗靶点，而rs1982809多态性有望成为波兰和突尼斯人群的癌症易感性标记。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nucleosides, Nucleotides & Nucleic Acids 生物-生化与分子生物学

CiteScore

2.60

自引率

7.70%

发文量

审稿时长

6 months

期刊介绍： Nucleosides, Nucleotides & Nucleic Acids publishes research articles, short notices, and concise, critical reviews of related topics that focus on the chemistry and biology of nucleosides, nucleotides, and nucleic acids. Complete with experimental details, this all-inclusive journal emphasizes the synthesis, biological activities, new and improved synthetic methods, and significant observations related to new compounds.